Sanofi, GSK To Provide Potential COVID-19 Vaccine To COVAX; Vaccine Nationalism Poses Challenges; Russia Applies For WHO Emergency Use Of Its Sputnik V Vaccine

AP: Sanofi, GSK to provide COVID-19 vaccine to global alliance
“Drugmakers Sanofi and GlaxoSmithKline have agreed to provide 200 million doses of their potential COVID-19 vaccine to the COVAX Facility, a collaboration designed to give countries around the world equal access to coronavirus vaccines…” (10/28).

Bloomberg: Sanofi, Glaxo to Supply 200 Million Covid Vaccine Doses to Covax
“…The drugmakers signed the supply arrangement with Gavi, the Vaccine Alliance, according to a statement. Gavi is among the groups working with the World Health Organization to ensure access to immunization for people around the world…” (Lauerman/Loh, 10/28).

POLITICO: The next vaccine challenge: Nationalism
“As scientists edge closer to a vaccine for Covid-19, a more vexing exercise may be ahead: overcoming the mounting forces of nationalism to get all those doses around the world…” (Savage, 10/28).

Reuters: Russia applies for WHO emergency use tag for its COVID-19 vaccine
“The Russian Direct Investment Fund (RDIF) has submitted applications to the World Health Organization for an Emergency Use Listing and prequalification of its coronavirus vaccine, Sputnik V, Russia’s sovereign wealth fund said on Tuesday…” (Chander, 10/27).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270 | Email Alerts: | |

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.